$QTTB

Q32 Bio Inc.

Q32 Bio is a clinical-stage biotechnology company developing biologic medicines for alopecia areata and other autoimmune and inflammatory diseases. Its main product candidate is bempikibart, a fully human antibody designed to block IL-7 and TSLP signaling. The company is evaluating it for alopecia areata in an ongoing Phase 2a trial and an open-label extension, following two completed Phase 2a trials in alopecia areata and atopic dermatitis. Q32 Bio also retains a tissue-targeted complement inhibitor platform, including early-stage asset ADX-096. It sold substantially all assets related to ADX-097 to Akebia Therapeutics, which is responsible for that program’s future development and commercialization. Q32 Bio’s work centers on research and clinical development; it contracts with third parties to manufacture, store and distribute its product candidates. It holds licenses and other rights related to its programs and may receive milestone payments and royalties under certain agreements. The company is headquartered in Waltham, Massachusetts.

AlphAI earnings readThird Quarter 2026 · NOV 4Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $QTTB in the last 7 days.

No SEC Form 4 filings for $QTTB in the last 30 days.

See all $QTTB insider activity →
Med

Q32 Bio GAAP EPS of -$0.26 beats by $0.07 (QTTB:NASDAQ)

Q32 Bio reported Q3 GAAP EPS of -$0.26, beating estimates by $0.07. The company had $289.6M in cash and cash equivalents as of September 30, 2026, and stated it has sufficient funds for operations.

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.

Oppenheimer reiterates Q32 Bio stock rating on durable trial data

Oppenheimer reiterated an Outperform rating and $40.00 price target for Q32 Bio (QTTB) after positive trial data for bempikibart in alopecia areata. The stock fell 13.2% on September 30, but remains up 149% year-to-date. Multiple analysts have raised price targets or initiated coverage with positive ratings, citing the drug's potential.

QTTB sentiment & insider activity

Recent QTTB coverage spans market movers, earnings and financial news.

What's driving QTTB

AlphAI scores every news story that mentions QTTB with an AI model for sentiment and relevance, and aggregates insider trades from Q32 Bio Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $QTTB

Score
$QTTBMedAI 8/10Earnings

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.

Why is Q32 Bio stock sliding today?

Q32 Bio Inc. (QTTB) stock fell 1.4% in pre-market trading, continuing volatility after its Phase 2a data presentation. Analysts remain bullish, with Oppenheimer and Jefferies maintaining positive outlooks. The broader market showed modest gains, supported by softer inflation data. The stock's decline is attributed to post-catalyst digestion rather than new negative developments.

$QTTBHighAI 8/10

Why is Q32 Bio stock surging today?

Q32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.

$QTTBHighAI 8/10

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio (QTTB) presented 36-week results from its SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata at EADV 2026. The drug showed clinically meaningful efficacy, with a 35.3% mean reduction in SALT scores. 40% of patients achieved SALT-20 response. The 16-week off-drug period showed durable responses, with 44% maintaining SALT-20. Q32 Bio plans to advance a registration-directed program in 2027.

$QTTBMedAI 8/10

Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart

Q32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.

$QTTBLowExec change· appointed

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer — Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage

$AAPLHighAI 8/10

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

Related tickers